Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment

Amgen

Status and phase: Completed; Phase 2

Conditions: Advanced Renal Cell Carcinoma; Solid Tumors; Prostate Cancer; Non-Small Cell Lung Cancer; Colorectal Cancer

Treatments: Drug: Panitumumab (ABX-EGF)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00425204

20020375

Abgenix Protocol No. ABX-0311

Details and patient eligibility

About

A multi-center, open-label, extended treatment, clinical trial examining the safety of administering multiple does of panitumumab by intravenous (i.v.) infusion to patients who have previously received panitumumab and benefited from treatment

Enrollment: 31 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Able to comprehend and sign an IRB approved Informed Consent Form
• Male or female 18 years of age or older
• Female patients who are post menopausal (no menstrual period for a minimum of six months), surgically sterilized, or are using an oral or implanted contraceptive, double barrier birth control, or an intrauterine device (IUD) and have a negative serum pregnancy test upon entry into this study; or male patients willing to use contraception upon enrollment and during the course of the study
• Previously received and tolerated panitumumab treatment on studies 20020374 Part 2 or 20030138/20040116
• Is considered "stable" or "responding" based on the RECIST (20020374 Part 2) or WHO (20040116) criteria, at the final treatment visit of the previous panitumumab clinical trial and the screening visit for this study
• No more than 2 months (60 days) have elapsed since the final treatment visit of the previous panitumumab clinical trial
• Karnofsky score > or = 70%

Exclusion criteria

• Brain metastases (20040116 patients are allowed only if controlled and asymptomatic)
• Uncontrolled hypercalcemia (calcium level outside the upper limit of normal; antihypercalcemic treatment is allowed). Exception: Patients in the Motzer Intermediate Risk Group from 20020374 Cohort 2 with uncontrolled high corrected calcium (>10 mg/dl) may be enrolled
• Use of any anti-tumor therapy or investigational drug, other than panitumumab, between the last visit of the previous panitumumab study and the initial visit in this 20020375 study
• Prior treatment with another anti-EGFr agent, other than panitumumab
• Myocardial infarction within 1 year prior to entering the study
• Has other cancer that has been active and required treatment within the past 5 years (basal cell carcinoma or cervical carcinoma in situ are allowed)
• Pregnant or breast feeding female; female of childbearing potential (defined as: post menarche and is biologically capable of becoming pregnant) unwilling to use birth control (as defined in the inclusion criteria) during and for 6 months following treatment
• Male patient unwilling to use birth control (as defined in the inclusion criteria) during and for 1 month following treatment
• Known to be HIV positive
• History of any chronic medical or psychiatric condition or laboratory abnormality that in the opinion of the Investigator may increase the risks associated with study drug administration
• Allergy to the ingredients of the study medication or to Staphylococcus Protein A
• History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

31 participants in 1 patient group

Open Label

Experimental group

Description:

Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.

Treatment:

Drug: Panitumumab (ABX-EGF)